首页> 外文期刊>Hepatitis Monthly >The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection
【24h】

The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection

机译:慢性丙型肝炎病毒感染患者血清中胞浆棒和环颗粒自身抗体的存在

获取原文
           

摘要

Background: Chronic hepatitis C virus (HCV) is associated with extra hepatic autoimmune disorders, while peg-IFNa-2a/RBV combination therapy may exacerbate these conditions. Autoantibodies to cytoplasmic structures, called rod and ring particles (RR), have strong associations with these patients and are identified by HEp-2 cells. Objectives: Our purpose was to study the correlation of autoantibodies to cytoplasmic rod and ring particles in the serum of patients with chronic HCV infection with their response to standard therapy. Methods: Serum samples were gathered from 120 patients with HCV infection (40 naive treatments, 40 with sustained virological response (SVR), and 40 with relapse response) during peg-IFNa-2a/RBV combination therapy and analyzed for the presence of RR antibodies by IIF on commercially available HEp-2 cell substrate slides from Euroimmun (Lu beck, Germany). Results: Anti-rod and ring (anti-RR) autoantibodies were detected in only the serum of 1 out of 120 patients (0.8%), which belonged to a patient (out of 40) with relapse response (2.5%). No correlation was found between the types of response to peg-IFNa-2a/RBV combination therapy and the presence of anti-RR autoantibodies. Conclusions: The only HCV patient with RR autoantibodies previously had received IFN/ribavirin antiviral therapy. The presence of these autoantibodies is extremely rare in Iranian HCV patients. Further studies are warranted to determine the role of genetic background and geographical pattern in the prevalence of these novel autoantibodies worldwide.
机译:背景:慢性丙型肝炎病毒(HCV)与额外的肝自身免疫性疾病有关,而peg-IFNa-2a / RBV联合治疗可能会加剧这些疾病。对细胞质结构的自身抗体,称为杆和环颗粒(RR),与这些患者有很强的联系,并由HEp-2细胞鉴定。目的:我们的目的是研究自身抗体与慢性HCV感染患者血清中胞浆棒和环颗粒的相关性及其对标准疗法的反应。方法:在peg-IFNa-2a / RBV联合治疗期间,从120例HCV感染患者(40例初治,40例持续病毒学应答(SVR)和40例复发应答)中收集血清样本,并分析其RR抗体的存在。由IIF在欧洲免疫(Euroimmun)(德国吕贝克)的HEp-2细胞底物载玻片上进行了研究。结果:仅在120例患者中有1例(0.8%)的血清中检测到抗杆和环(anti-RR)自身抗体,该患者属于复发反应患者(40%)(2.5%)。在对peg-IFNa-2a / RBV联合疗法的反应类型与抗RR自身抗体的存在之间未发现相关性。结论:仅有的具有RR自身抗体的HCV患者以前曾接受过IFN /利巴韦林抗病毒治疗。这些自身抗体的存在在伊朗HCV患者中极为罕见。有必要进行进一步的研究以确定遗传背景和地理模式在全世界这些新型自身抗体的流行中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号